drugset / Trial / NCT06733298

A Study Investigating [14C]-Labeled RO7269162 in Healthy Male Participants

NCT06733298 ↗

Phase 1 Completed 8 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This study will investigate how RO7269162 labeled with a carbon tracer (\[14C\]) is absorbed, metabolized, and eliminated by the body after a single dose in healthy male volunteers.

Timeline

Start
2025-01-08
Primary completion
2025-01-29
Completion
2025-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject RO7269162 Unknown — Oral

Indications

No indication recorded.